Picture loading failed.

Pre-Made Telisotuzumab biosimilar, Whole mAb ADC, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Telisotuzumab vedotin, also known as ABBV 399 (ABBV-399; ABT 399), is a novel, first-in-class, investigational antibody-drug conjugate being developed by AbbVie comprised of the anti-c-Met antibody, ABT-700, directed against the cell surface glycoprotein mesothelia, conjugated to monomethyl auristatin E (MMAE) for the treatment of patients with solid tumors.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-559-1mg 1mg 4635
GMP-Bios-ab-559-10mg 10mg Inquiry
GMP-Bios-ab-559-100mg 100mg Inquiry
GMP-Bios-ab-559-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Telisotuzumab biosimilar, Whole mAb ADC, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
INN Name Telisotuzumab
TargetMET
FormatWhole mAb ADC
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesPierre Fabre;AbbVie
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours
Development Techna